Development and Evaluation of Nanostructured Lipid Carriers of Cytarabine for Treatment of Meningeal Leukemia

2011 ◽  
Vol 11 (8) ◽  
pp. 6676-6682 ◽  
Author(s):  
Praveen Sharma ◽  
Brahmanand Dube ◽  
Krutika Sawant
Keyword(s):  
Nanostructured Lipid Carriers ◽  
Meningeal Leukemia

Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity

2017 ◽  
Vol 14 (8) ◽  
Author(s):  
Mahboubeh Rezazadeh ◽  
Jaber Emami ◽  
Farshid Hassanzadeh ◽  
Hojjat Sadeghi ◽  
Mahboubeh Rostami ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Nanostructured Lipid Carriers ◽  
Cell Toxicity

Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review

2011 ◽  
Vol 6 (4) ◽  
pp. 240-250 ◽  
Author(s):  
Rajashree Hirlekar ◽  
Harshal Garse ◽  
Vilasrao Kadam
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Nanostructured Lipid Carriers ◽  
Solid Lipid

Meningeal Leukemia following Lymphoid Blast Crisis in Chronic Myeloid Leukemia: Therapeutic Implications

1982 ◽  
Vol 68 (3) ◽  
pp. 257-263 ◽  
Author(s):  
Mario Cazzola ◽  
Giulio Nalli ◽  
Ercole Brusamolino ◽  
Maurizio Daccò ◽  
Angela Ghizzi ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Chronic Myeloid Leukemia ◽  
Complete Remission ◽  
Myeloid Leukemia ◽  
Lymphoblastic Leukemia ◽  
Blast Crisis ◽  
Early Prevention ◽  
Therapeutic Implications ◽  
Therapeutic Protocol ◽  
Meningeal Leukemia

Five of 40 patients with chronic myeloid leukemia (CML) had lymphoid blast crisis and 4 of them achieved complete remission of metamorphosis with vincristine and prednisone. While in hematologic remission, two of these subjects developed meningeal leukemia. Clinical and biologic data indicated that the course of the disease after lymphoid blast crisis was very similar to that of acute lymphoblastic leukemia (ALL). It is suggested that patients with CML who develop lymphoid blast crisis should be treated with an intensive therapeutic protocol including early prevention of meningeal leukemia.

scholarly journals Optimization of Tilmicosin-Loaded Nanostructured Lipid Carriers Using Orthogonal Design for Overcoming Oral Administration Obstacle

Pharmaceutics ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 303
Author(s):  
Jia Wen ◽  
Xiuge Gao ◽  
Qian Zhang ◽  
Benazir Sahito ◽  
Hongbin Si ◽  
...  
Keyword(s):  
Oral Administration ◽  
Oral Delivery ◽  
Bacterial Infections ◽  
Cold Water ◽  
Orthogonal Design ◽  
Drug Loading ◽  
Absorption Efficiency ◽  
Nanostructured Lipid Carriers ◽  
Orthogonal Experimental Design ◽  
Hydrodynamic Diameter

Tilmicosin (TMS) is widely used to treat bacterial infections in veterinary medicine, but the clinical effect is limited by its poor solubility, bitterness, gastric instability, and intestinal efflux transport. Nanostructured lipid carriers (NLCs) are nowadays considered to be a promising vector of therapeutic drugs for oral administration. In this study, an orthogonal experimental design was applied for optimizing TMS-loaded NLCs (TMS-NLCs). The ratios of emulsifier to mixed lipids, stearic acid to oleic acid, drugs to mixed lipids, and cold water to hot emulsion were selected as the independent variables, while the hydrodynamic diameter (HD), drug loading (DL), and entrapment efficiency (EE) were the chosen responses. The optimized TMS-NLCs had a small HD, high DL, and EE of 276.85 ± 2.62 nm, 9.14 ± 0.04%, and 92.92 ± 0.42%, respectively. In addition, a low polydispersity index (0.231 ± 0.001) and high negative zeta potential (−31.10 ± 0.00 mV) indicated the excellent stability, which was further demonstrated by uniformly dispersed spherical nanoparticles under transmission electron microscopy. TMS-NLCs exhibited a slow and sustained release behavior in both simulated gastric juice and intestinal fluid. Furthermore, MDCK-chAbcg2/Abcb1 cell monolayers were successfully established to evaluate their absorption efficiency and potential mechanism. The results of biodirectional transport showed that TMS-NLCs could enhance the cellular uptake and inhibit the efflux function of drug transporters against TMS in MDCK-chAbcg2/Abcb1 cells. Moreover, the data revealed that TMS-NLCs could enter the cells mainly via the caveolae/lipid raft-mediated endocytosis and partially via macropinocytosis. Furthermore, TMS-NLCs showed the same antibacterial activity as free TMS. Taken together, the optimized NLCs were the promising oral delivery carrier for overcoming oral administration obstacle of TMS.

Sign in / Sign up

Export Citation Format

Share Document